Petros Pharmaceuticals (PTPI) Short Interest Ratio & Short Volume → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Buy PTPI with Qtrade Free PTPI Stock Alerts $1.48 +0.03 (+2.07%) (As of 03/28/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Petros Pharmaceuticals Short Interest DataCurrent Short Volume88,400 sharesPrevious Short Volume317,200 sharesChange Vs. Previous Month-72.13%Dollar Volume Sold Short$134,368.00Short Interest Ratio / Days to Cover0.1Last Record DateMarch 15, 2024Outstanding Shares2,200,000 sharesFloat Size1,310,000 sharesShort Percent of Float6.75%Today's Trading Volume367,507 sharesAverage Trading Volume910,944 sharesToday's Volume Vs. Average40% Short Selling Petros Pharmaceuticals ? Sign up to receive the latest short interest report for Petros Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatPTPI Short Interest Over TimePTPI Days to Cover Over TimePTPI Percentage of Float Shorted Over Time Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> Petros Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/202488,400 shares $134,368.00 -72.1%6.8%0.1 $1.52 2/29/2024317,200 shares $545,584.00 +12.3%24.2%0.3 $1.72 2/15/2024282,400 shares $434,896.00 +16.5%21.9%0.3 $1.54 1/31/2024242,400 shares $293,304.00 +2,208.6%18.8%0.4 $1.21 1/15/202410,500 shares $13,807.50 -74.8%0.8%0 $1.32 12/31/202341,700 shares $58,797.00 -66.5%3.1%0.2 $1.41 Get the Latest News and Ratings for PTPI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Petros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 12/15/2023124,300 shares $172,777.00 +571.9%9.1%0.6 $1.39 11/30/202318,500 shares $29,600.00 -28.3%1.4%0.2 $1.60 11/15/202325,800 shares $34,314.00 -41.6%2.0%0.8 $1.33 10/31/202344,200 shares $63,206.00 -27.9%3.5%1.3 $1.43 10/15/202361,300 shares $98,073.87 +415.1%4.9%1.4 $1.60 9/30/202311,900 shares $20,585.81 +213.2%0.9%0 $1.73 9/15/20233,800 shares $6,878.00 -82.3%0.3%0 $1.81 8/31/202321,500 shares $54,825.00 -62.7%1.7%0.1 $2.55 8/15/202357,700 shares $184,640.00 -21.9%3.9%0.2 $3.20 7/31/202373,900 shares $296,339.00 -79.4%5.0%0.2 $4.01 7/15/2023359,100 shares $1.14 million +1,330.7%24.3%0.5 $3.19 6/30/202325,100 shares $50,953.00 -27.0%1.7%0 $2.03 6/15/202334,400 shares $89,784.00 -10.7%2.3%0 $2.61 5/31/202338,500 shares $89,705.00 -13.5%2.6%0 $2.33 5/15/202344,500 shares $186,900.00 -88.5%3.0%0 $4.20 4/30/2023385,300 shares $1.66 million +1,029.9%27.3%0.2 $4.30 4/15/202334,100 shares $156,519.00 -22.5%2.4%0 $4.59 3/31/202344,000 shares $61,380.00 +14.9%3.1%3.1 $1.40 3/15/202338,300 shares $56,684.00 +13.0%2.7%2.1 $1.48 2/28/202333,900 shares $71,190.00 -6.6%2.4%1.6 $2.10 2/15/202336,300 shares $92,202.00 +23.1%2.5%1.8 $2.54 1/31/202329,500 shares $76,700.00 -24.4%2.1%1.5 $2.60 1/15/202339,000 shares $118,950.00 +14.0%2.7%1.6 $3.05 12/30/202234,200 shares $79,686.00 +14.8%2.4%1.4 $2.33 12/15/202229,800 shares $63,176.00 +43.3%2.1%1.8 $2.12 11/30/202220,800 shares $8,550.88 -92.2%1.4%1.5 $0.41 11/15/2022265,700 shares $130,193.00 +78.6%N/A2.1 $0.49 10/31/2022148,800 shares $71,424.00 +9.3%N/A1 $0.48 10/15/2022136,200 shares $58,525.14 +77.3%N/A0.2 $0.43 9/30/202276,800 shares $39,168.00 -36.1%N/A0.1 $0.51 9/15/2022120,200 shares $78,682.92 -7.1%N/A0.1 $0.65 8/31/2022129,400 shares $84,821.70 +45.4%N/A0.1 $0.66 8/15/202289,000 shares $71,627.20 +420.5%N/A0.1 $0.80 7/31/202217,100 shares $13,573.98 -22.3%N/A0 $0.79Central Banks Preparing for US Dollar Collapse? (Ad)China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> PTPI Short Interest - Frequently Asked Questions What is Petros Pharmaceuticals' current short interest? Short interest is the volume of Petros Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of March 15th, traders have sold 88,400 shares of PTPI short. 6.75% of Petros Pharmaceuticals' shares are currently sold short. Learn More on Petros Pharmaceuticals' current short interest. Which institutional investors are shorting Petros Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Petros Pharmaceuticals: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Petros Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 6.75% of Petros Pharmaceuticals' floating shares are currently sold short. Is Petros Pharmaceuticals' short interest increasing or decreasing? Petros Pharmaceuticals saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 88,400 shares, a drop of 72.1% from the previous total of 317,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Petros Pharmaceuticals' float size? Petros Pharmaceuticals currently has issued a total of 2,200,000 shares. Some of Petros Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Petros Pharmaceuticals currently has a public float of 1,310,000 shares. How does Petros Pharmaceuticals' short interest compare to its competitors? 6.75% of Petros Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Petros Pharmaceuticals: Jaguar Health, Inc. (14.66%), Kintara Therapeutics, Inc. (5.64%), Atreca, Inc. (0.37%), PainReform Ltd. (1.02%), Onconetix, Inc. (3.83%), PaxMedica, Inc. (8.77%), Altamira Therapeutics Ltd. (3.91%), Notable Labs, Ltd. (0.13%), Aravive, Inc. (1.81%), Biophytis S.A. (0.44%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Cummins Inc. ($8.93 billion), Canadian Natural Resources Limited ($7.79 billion), Super Micro Computer, Inc. ($4.31 billion), T-Mobile US, Inc. ($4.00 billion), General Motors ($3.36 billion), Occidental Petroleum Co. ($3.10 billion), Charter Communications, Inc. ($2.92 billion), Coinbase Global, Inc. ($2.74 billion), Tractor Supply ($2.72 billion), and Moderna, Inc. ($2.31 billion). View all of the most shorted stocks. What does it mean to sell short Petros Pharmaceuticals stock? Short selling PTPI is an investing strategy that aims to generate trading profit from Petros Pharmaceuticals as its price is falling. PTPI shares are trading up $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Petros Pharmaceuticals? A short squeeze for Petros Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of PTPI, which in turn drives the price of the stock up even further. How often is Petros Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PTPI, twice per month. The most recent reporting period available is March, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Jaguar Health Short Squeeze Kintara Therapeutics Short Squeeze Atreca Short Squeeze PainReform Short Squeeze Onconetix Short Squeeze PaxMedica Short Squeeze Altamira Therapeutics Short Squeeze Notable Labs Short Squeeze Aravive Short Squeeze Biophytis Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:PTPI) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & CompanyMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research